GlassScriptPhysician profile
Richard C Agnew
NPI 1629089206
$520.45
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $1.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.05 | 2019 | |
| Allergan, INC. | $140.78 | 2019 | |
| Vertical Pharmaceuticals, LLC | $36.02 | 2019 | |
| Forte Bio-Pharma LLC | $34.55 | 2019-2020 | |
| Therapeuticsmd, INC. | $28.68 | 2019 | |
| Novo Nordisk INC | $27.60 | 2019 | |
| Akcea Therapeutics, INC. | $19.87 | 2019 | |
| Astellas Pharma US INC | $19.17 | 2019 | |
| Coopersurgical, INC. | $13.56 | 2019 | |
| Pfizer INC. | $13.32 | 2019 | |
| Convatec INC. | $11.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Agnew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.